Kevin Shannon, MD

Education
Post-Doc Fellow/Scholar, 1988 - Pediatric Hematology/Oncology, UCSF
Residency, 1982 - Pediatrics, UT Southwestern
M.D., 1979 - Medicine, Cornell University Medical College
Honors and Awards
  • UCSF Faculty Basic Science Lectureship, UCSF, 2020
  • Research Prize for Contributions to Pediatric Oncology, Society of Memorial Sloan Kettering, 2019
  • Team Science Research Award, Children’s Tumor Foundation, 2016
  • Research Professor Award, American Cancer Society, 2010-2020
  • MERIT Award, National Cancer Institute, 2007-2017
  • Roma & Marvin Auerback Distinguished Professor in Molecular Oncology, UCSF, 2000

  1. Moore JP, Su J, Shannon KM, Perens GS, Newlon C, Bradfield JS, Shivkumar K. Multidetector Computed Tomography Assessment of Anatomical Ventricular Tachycardia Isthmuses in Repaired Tetralogy of Fallot. JACC. Clinical electrophysiology 2024. PMID: 38456860


  2. Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. JCI insight 2023. PMID: 37681415


  3. Moore JP, Shannon KM, Khairy P, Waldmann V, Bessière F, Burrows A, Su J, Shivkumar K. Sinus rhythm QRS morphology reflects right ventricular activation and anatomical ventricular tachycardia isthmus conduction in repaired tetralogy of Fallot. Heart rhythm 2023. PMID: 37598989


  4. Levinson A, Tjoa K, Huang BJ, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon KM, Wandler A. Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL. Blood advances 2023. PMID: 36897249


  5. Blakeley JO, Shannon K. Precision Oncology for Papillary Craniopharyngioma. The New England journal of medicine 2023. PMID: 37437149


  6. Shannon K. The CCDI Comes Out of the Starting Block. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 37319399


  7. Huang BJ, Shannon K. NFIA-ETO2, TP53, and erythroid leukemogenesis. Blood 2023. PMID: 37140954


  8. Popescu B, Shannon K. Sidestepping SHP2 inhibition. The Journal of experimental medicine 2023. PMID: 36880733


  9. de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, Robison N, Schorry EK, Shannon K, Stevenson DA, Stieglitz E, Ullrich NJ, Walsh KS, Weiss BD, Wolters PL, Yohay K, Yohe ME, Widemann BC, Fisher MJ. MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus. Neuro-oncology 2022. PMID: 35788692


  10. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 2022. PMID: 36002574


  11. Suciu RM, Luvaga IK, Hazeen A, Weerasooriya C, Richardson SK, Firestone AJ, Shannon K, Howell AR, Cravatt BF. Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorganic & medicinal chemistry letters 2021. PMID: 34666187


  12. Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nature chemical biology 2021. PMID: 33927411


  13. Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI insight 2020. PMID: 32990679


  14. Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Molecular cancer therapeutics 2020. PMID: 32847978


  15. Shannon K, Link DC. Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. 2020. PMID: 34661135


  16. Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood 2020. PMID: 32219446


  17. Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, Yamamoto K, Sampath D, Nakitandwe J, Downing JR, Zhang J, Aster JC, Taylor BS, Shannon K. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia 2020. PMID: 32066867


  18. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. The Journal of clinical investigation 2020. PMID: 31687977


  19. Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison LL, Clapp DW, Shannon K, Nakamura JL, Fisher MJ. Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 31532722


  20. Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. PloS one 2019. PMID: 31318944


  21. Huang BJ, Wandler AM, Meyer LK, Dail M, Daemen A, Sampath D, Li Q, Wang X, Wong JC, Nakitandwe J, Downing JR, Zhang J, Taylor BS, Shannon K. Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. PLoS genetics 2019. PMID: 31199785


  22. Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell reports 2019. PMID: 30970263


  23. Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS. Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer cell 2018. PMID: 30393068


  24. Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, Klco JM. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI insight 2018. PMID: 30046003


  25. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell stem cell 2018. PMID: 29910151


  26. Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PloS one 2018. PMID: 29799846


  27. Wandler A, Shannon K. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harbor perspectives in medicine 2018. PMID: 28778967


  28. Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer research 2017. PMID: 28993414


  29. Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell 2017. PMID: 28215705


  30. Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature medicine 2017. PMID: 28191887


  31. Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, Smirnoff IV, Horvai AE, Loh M, DuBois SG, Goldsby RE, Neglia JP, Hammond S, Robison LL, Wustrack R, Costello JF, Nakamura AO, Shannon KM, Bhatia S, Nakamura JL. Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clinical cancer research : an official journal of the American Association for Cancer Research 2016. PMID: 27683180


  32. Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica 2016. PMID: 27418650


  33. White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature communications 2016. PMID: 26854029


  34. Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM. KRAS Engages AGO2 to Enhance Cellular Transformation. Cell reports 2016. PMID: 26854235


  35. Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. eLife 2015. PMID: 26193121


  36. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature genetics 2015. PMID: 25822087


  37. Shannon KM. CCR4 drives ATLL jail break. The Journal of experimental medicine 2014. PMID: 25512583


  38. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood 2014. PMID: 25361812


  39. Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood 2014. PMID: 25316678


  40. Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 2014. PMID: 25043004


  41. Shannon K, Hermiston M. A(nother) RAF mutation in LCH. Blood 2014. PMID: 24832939


  42. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer cell 2014. PMID: 24794707


  43. Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood 2014. PMID: 24578498


  44. North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD. Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC cancer 2014. PMID: 24386979


  45. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Science signaling 2013. PMID: 24300897


  46. Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature 2013. PMID: 24284627


  47. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2013. PMID: 24178622


  48. Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013. PMID: 23818547


  49. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer discovery 2013. PMID: 23733505


  50. Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood 2013. PMID: 23637129


  51. Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Science signaling 2013. PMID: 23532335


  52. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. The Journal of clinical investigation 2012. PMID: 23221337


  53. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012. PMID: 22898602


  54. Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis. Blood 2012. PMID: 22500049


  55. Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 2011. PMID: 22144181


  56. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Science translational medicine 2011. PMID: 21451123


  57. Shannon K, Li Q. Oncogenic Ras scales the ALPS. Blood 2011. PMID: 21393497


  58. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood 2011. PMID: 21398220


  59. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer research 2011. PMID: 21199799


  60. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2010. PMID: 21163920


  61. Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. The New England journal of medicine 2010. PMID: 21067376


  62. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. The Journal of experimental medicine 2010. PMID: 21059853


  63. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes & development 2010. PMID: 20595231


  64. Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood 2010. PMID: 20233966


  65. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proceedings of the National Academy of Sciences of the United States of America 2010. PMID: 20194733


  66. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. American journal of medical genetics. Part A 2010. PMID: 20014119


  67. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009. PMID: 19727076


  68. Shannon K, Loh M. Cancer: More than kin and less than kind. Nature 2009. PMID: 19675635


  69. Braun BS, Shannon K. The SPS affair: a complex tale of illicit proliferation. Cancer cell 2009. PMID: 19647218


  70. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009. PMID: 19571318


  71. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS biology 2009. PMID: 19296721


  72. Wong JC, Le Beau MM, Shannon K. Tumor suppressor gene inactivation in myeloid malignancies. Best practice & research. Clinical haematology 2008. PMID: 19041599


  73. Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 2008. PMID: 18948576


  74. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer cell 2008. PMID: 18835035


  75. Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood 2008. PMID: 18818388


  76. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research 2008. PMID: 18413813


  77. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature genetics 2008. PMID: 18372904


  78. Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Human mutation 2008. PMID: 17979197


  79. Shannon KM, Le Beau MM. Cancer: hay in a haystack. Nature 2008. PMID: 18202630


  80. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2007. PMID: 18000167


  81. Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Molecular and cellular biology 2007. PMID: 17875937


  82. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes & development 2007. PMID: 17699748


  83. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature reviews. Cancer 2007. PMID: 17384584


  84. Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD. Abnormal hematopoiesis in Gab2 mutant mice. Blood 2007. PMID: 17374739


  85. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Current opinion in genetics & development 2007. PMID: 17208427


  86. Shannon K, Bollag G. Sending out an SOS. Nature genetics 2007. PMID: 17192780


  87. Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 2006. PMID: 17192389


  88. Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell cycle (Georgetown, Tex.) 2006. PMID: 16921267


  89. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 2006. PMID: 16720837


  90. Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 2006. PMID: 16690971


  91. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric blood & cancer 2006. PMID: 16261595


  92. Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. The Journal of clinical investigation 2006. PMID: 16585951


  93. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006. PMID: 16493009


  94. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. Nature genetics 2006. PMID: 16474405


  95. Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer cell 2005. PMID: 16226708


  96. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005. PMID: 15886328


  97. Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 2005. PMID: 15820312


  98. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer cell 2005. PMID: 15837617


  99. Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K. Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. The Journal of experimental medicine 2005. PMID: 15781578


  100. Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005. PMID: 15761018


  101. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer cell 2004. PMID: 15607959


  102. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes, chromosomes & cancer 2004. PMID: 14732923


  103. Braun BS, Shannon K. The sum is greater than the FGFR1 partner. Cancer cell 2004. PMID: 15050910


  104. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004. PMID: 14982883


  105. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Current opinion in hematology 2004. PMID: 14676626


  106. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America 2003. PMID: 14699048


  107. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2003. PMID: 14644997


  108. Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proceedings of the National Academy of Sciences of the United States of America 2003. PMID: 14500898


  109. Kratz CP, Antonietti L, Shannon KM, Dole MG, Friebert SE. Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1. Journal of pediatric hematology/oncology 2003. PMID: 12679655


  110. Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials. Current opinion in genetics & development 2003. PMID: 12573440


  111. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer cell 2002. PMID: 12498712


  112. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer cell 2002. PMID: 12498719


  113. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clinical cancer research : an official journal of the American Association for Cancer Research 2002. PMID: 12473573


  114. Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood 2002. PMID: 12433685


  115. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer cell 2002. PMID: 12204529


  116. Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 2002. PMID: 12101424


  117. Le DT, Shannon KM. Ras processing as a therapeutic target in hematologic malignancies. Current opinion in hematology 2002. PMID: 12042705


  118. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochimica et biophysica acta 2002. PMID: 11960693


  119. Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM. Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood 2002. PMID: 11756194